Appointment of Non-Executive Director

RNS Number : 1763N

Angle PLC

19 January 2023

 

For immediate release

19 January 2023

ANGLE plc ("the Company")

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

Joseph Eid M.D., is a US certified medical oncologist with extensive experience of the use of biomarkers in clinical trials and as companion diagnostics

Previous roles include senior positions in oncology at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that Joseph (Joe) Eid M.D. has been appointed as a Non-Executive Director of the Company, with effect from 19 January 2023.

Joe is a qualified physician, board certified in medical oncology, haematology, and internal medicine.  He is a highly experienced pharmaceutical industry executive with over 25 years of proven expertise in people and portfolio management, planning, designing, and executing Phase I to IV clinical trials and building and managing clinical and medical affairs teams and strategies. He has successfully designed and implemented clinical development, medical affairs, and life cycle management plans for pharmaceutical products including cytotoxic agents, monoclonal antibodies, immuno-oncology agents, antibody-drug conjugates, and CAR-T Cell therapies.

Joe most recently served as Chief Medical Officer and Head of Global Drug Development for Princeton, New Jersey based Luzsana Biotechnology (a wholly owned subsidiary of Jiangsu Hengrui Pharmaceutical). Importantly, his previous experience includes senior positions in clinical development and medical affairs at Bristol Myers Squibb, Merck & Co. and Hoffman-La Roche.

Whilst at Merck, Joe led the global Keytruda^® (pembrolizumab, MK-3475) first-in-human strategy, including oversight of the clinical, regulatory, and manufacturing planning and execution and development of the PD-L1 biomarker strategy on tissue biopsy, which led to a first-in-class anti-PD-1 BLA filing and approval in the US.

Joseph Eid M.D., commented:

"I believe that ANGLE's Parsortix technology and unique liquid biopsy approach has enormous potential both in oncology drug development and in the clinical setting. I look forward to leveraging my extensive experience of the development and use of biomarkers in oncology to drive forward the Company's strategy and to using my network of pharma industry, clinical and academic thought leaders to accelerate the Company's commercial development."

ANGLE Chairman, Garth Selvey, added:

"We are delighted that Joe has agreed to join the ANGLE Board. Joe brings valuable knowledge and experience in oncology drug development and the use of biomarkers in the clinical trials process and as companion diagnostics. This is a key focus for the Company's pharma services business and will be of enormous benefit going forward."

Other than as disclosed below, there are no further disclosures to be made in connection with Joseph Emile Eid (age 55) in accordance with AIM Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for Companies:

Current	Previous
Joseph Eid Biopharma Consulting LLC	Luzsana Biotechnology, Inc
Luminary Therapeutics, Inc	Bristol Myers Squibb

For further information:

ANGLE plc	[phone]
Andrew Newland, Chief Executive Ian Griffiths, Finance Director Andrew Holder, Head of Investor Relations
Berenberg (NOMAD and Joint Broker) Toby Flaux, Ciaran Walsh, Milo Bonser	[phone]
Jefferies (Joint Broker) Thomas Bective, Shaam Vora	[phone]
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	[phone] [phone]

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) . Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected circulating tumor cell (CTC) harvesting technology is known as the Parsortix^® system.

ANGLE's Parsortix^® system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA cleared medical device to harvest intact circulating cancer cells from blood.

Intended use

The Parsortix^® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K₂EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

The Parsortix system enables a liquid biopsy (a simple blood test) to be used to provide the circulating metastatic breast cancer cells to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all phenotypes of CTCs (epithelial, mesenchymal and EMTing CTCs) as well as CTC clusters in a viable form (alive). CTCs harvested from the system enable a complete picture of a cancer to be seen; as being an intact cell they allow DNA, RNA and protein analysis as well as cytological and morphological examination and may provide comparable analysis to a tissue biopsy in metastatic breast cancer. Because CTC analysis is a non-invasive process, unlike tissue biopsy, it can be repeated as often as needed. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information on the status of a patient's tumor. In addition, the live CTCs harvested by the Parsortix system can be cultured, which offers the potential for testing tumor response to drugs outside the patient.

The Parsortix technology is the subject of 26 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide.

In the United States, the Parsortix^® PC1 system has received a Class II Classification from FDA for use with metastatic breast cancer patients. FDA clearance is seen as the global gold standard. ANGLE's Parsortix system is the first ever FDA cleared system for harvesting CTCs for subsequent analysis. ANGLE has applied the IVD CE Mark to the same system for the same intended use in Europe.

ANGLE has also completed three separate 200 subject clinical studies under a programme designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (AUC-ROC) of 95.4% with sensitivity of 90% and specificity of 93%. This excellent clinical result demonstrates the utility of cells harvested by the Parsortix system, which the Company believes is the "best sample" for liquid biopsy analysis as it recovers intact, living cancer cells that are involved in the progression of the disease providing prospective information.

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 76 peer-reviewed publications and numerous publicly available posters from 33 independent cancer centres, available on our website.

ANGLE has established clinical services laboratories in the UK and the United States to accelerate commercialisation of the Parsortix system and act as demonstrators to support product development. The laboratories offer services globally to pharmaceutical and biotech customers for use of Parsortix in cancer drug trials and, once the laboratories are accredited and tests validated, will provide Laboratory Developed Tests (LDTs) for patient management.

 

END

 

 

BOAFZGMMVRLGFZM